Overview
XOMA is currently engaged in more than 16 active development projects across multiple therapeutic areas including inflammatory, autoimmune and infectious disease, and cancer. We develop both proprietary and partnered products using our extensive suite of antibody technologies. We are growing and advancing a rich pipeline of antibody therapeutics, and we have contributed to the development of three products that are currently marketed by Genentech and UCB, for which we received royalty payments of approximately $17 million in 2007.
Our pipeline of drug candidates includes XOMA 052, a paradigm-changing antibody for treatment of patients with Type 2 diabetes. We are currently evaluating XOMA 052 in two clinical studies of Type 2 diabetes patients for its potential to target key inflammatory pathways that contribute to the death and impairment of insulin-producing cells. We plan to advance XOMA 052 into additional clinical studies for the treatment of other inflammatory conditions, including acute gout, systemic juvenile idiopathic arthritis and rheumatoid arthritis.
In preclinical studies, XOMA 052 was well tolerated and demonstrated anti-inflammatory effects in animal models of arthritis and Type 2 diabetes.
Our unique topical treatment for skin infections, XOMA 629, is a gel formulation of a synthetic peptide derived from a human host-defense protein. XOMA 629 is currently under evaluation in a Phase 2A study in patients with the common skin infection, impetigo. Additional studies of XOMA 629 are planned for the topical eradication of infectious pathogens including Staphylococcus aureus (S. aureus) and methicillin-sensitive S. aureus (MSSA) and impetigo.
In addition to developing exciting proprietary antibody product candidates, our research teams have contributed to the development of approved antibody therapies including RAPTIVA®, marketed by Genentech for the treatment of moderate to severe plaque psoriasis. We have also contributed significantly to the development of HCD122, a monoclonal antibody to CD40 partnered with Novartis, and numerous other discovery and development projects.
